Market open
$
214.76
Change
+1.06 +0.50%
Volume
Volume 1.05m
Sep 25, 2023, 1:43 p.m.
Real time quotes
Previous close
$ 213.70
$ 214.76
Change
+1.06 +0.50%
Day low
Day high
$213.22
$214.81

52 week low
52 week high
$116.08
$214.81

Market cap
$40.11B
Average volume
1.21M
P/E ratio
N/A
Rev. per Employee
$664,005
EPS
-3.89
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on SGEN
-
Incyte Corp. stock underperforms Friday when compared to competitors
- MarketWatch Automation
-
Incyte Corp. stock underperforms Thursday when compared to competitors
- MarketWatch Automation
-
Incyte Corp. stock falls Wednesday, still outperforms market
- MarketWatch Automation
-
Incyte Corp. stock outperforms market on strong trading day
- MarketWatch Automation
-
Incyte Corp. stock falls Monday, underperforms market
- MarketWatch Automation
-
Incyte Corp. stock underperforms Friday when compared to competitors
- MarketWatch Automation
-
Incyte Corp. stock rises Thursday, still underperforms market
- MarketWatch Automation
-
Incyte Corp. stock falls Wednesday, underperforms market
- MarketWatch Automation
-
Incyte Corp. stock outperforms market despite losses on the day
- MarketWatch Automation
-
Incyte Corp. stock rises Monday, still underperforms market
- MarketWatch Automation
-
Incyte Corp. stock outperforms competitors on strong trading day
- MarketWatch Automation
-
Incyte Corp. stock outperforms market on strong trading day
- MarketWatch Automation
-
Incyte Corp. stock outperforms market despite losses on the day
- MarketWatch Automation
-
Incyte Corp. stock underperforms Tuesday when compared to competitors
- MarketWatch Automation
-
Incyte Corp. stock outperforms market on strong trading day
- MarketWatch Automation
-
Amgen, FTC Settle Over $27.8 Billion Horizon Deal
- Barron's Online
-
Incyte Corp. stock falls Thursday, underperforms market
- MarketWatch Automation
- Loading more headlines...
Analyst Ratings
-
Wall Street Is Bullish on Nektar Stock despite Stock Price Slump
- MarketRealist.com
-
Benzinga's Top Upgrades, Downgrades For October 20, 2017
- Benzinga.com
-
Shkreli: I'd Short Immunomedics On The Bounce
- Benzinga.com
Other News on SGEN
-
The Hedge Fund That Made a Killing Betting Against Lina Khan
- The Wall Street Journal Interactive Edition
-
S&P 500 Drops for Third Straight Week
- The Wall Street Journal Interactive Edition
-
Biden FTC’s Antitrust Bark Proves Worse Than Its Bite
- The Wall Street Journal Interactive Edition
-
Pfizer’s Covid Boost Crashes to Earth
- The Wall Street Journal Interactive Edition
-
Deal Activity Slumps as Pricing Proves to Be a Sticking Point
- The Wall Street Journal Interactive Edition
-
FTC’s Amgen Activism Will Spare Smaller Biotechs
- The Wall Street Journal Interactive Edition
-
Pfizer’s Earnings Fall With Cooling Demand for Covid-19 Products
- The Wall Street Journal Interactive Edition
-
Starbucks, Ford, Apple Lead Another Busy Earnings Week
- The Wall Street Journal Interactive Edition
-
- Edgar Online - (EDG = 10Q, 10K)
-
Bristol-Myers CEO Giovanni Caforio to Step Down
- The Wall Street Journal Interactive Edition
-
How to Tell Biotech’s Likely Winners From Losers
- The Wall Street Journal Interactive Edition
-
Merck to Buy Prometheus Biosciences
- The Wall Street Journal Interactive Edition
-
First Republic Bank, T-Mobile, Credit Suisse: Stocks That Defined the Week
- The Wall Street Journal Interactive Edition
-
- The Wall Street Journal Interactive Edition
-
Pfizer Agrees to Buy Seagen for $43 Billion
- The Wall Street Journal Interactive Edition
-
Pfizer Overpays for Seagen, but Who’s Counting
- The Wall Street Journal Interactive Edition
-
Seagen’s Cancer Therapy Is Making It a Takeover Target
- The Wall Street Journal Interactive Edition
-
Stocks Inch Up After Indexes Post Worst Week of 2023
- The Wall Street Journal Interactive Edition
-
Pfizer Is Eyeing a Deal With Seagen After Merck's Failure
- GuruFocus.com
-
Pfizer Is in Early-Stage Talks to Acquire Seagen
- The Wall Street Journal Interactive Edition
- Loading more headlines...
Press Releases on SGEN
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGEN, SPPI, HOTH
- PR Newswire - PRF
-
Seagen Reports First Quarter 2023 Financial Results
- BusinessWire - BZX
-
MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting
- BusinessWire - BZX
-
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates SGEN, UNVR, CVT
- PR Newswire - PRF
-
Seagen to Report First Quarter 2023 Financial Results on April 27, 2023
- BusinessWire - BZX
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TA, SGEN, UNVR, USX
- PR Newswire - PRF
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com